BRIEF-TYK Medicines' Asandeutertinib (TY-9591) To Be Included In List Of Products For Priority Review

Like
Comment
Favorite

BRIEF-TYK Medicines' Asandeutertinib (TY-9591) To Be Included In List Of Products For Priority Review

Reuters01-07

BRIEF-TYK Medicines' Asandeutertinib (TY-9591) To Be Included In List Of Products For Priority Review

Jan 7 (Reuters) - TYK Medicines Inc 2410.HK:

ASANDEUTERTINIB (TY-9591) TO BE INCLUDED IN LIST OF PRODUCTS FOR PRIORITY REVIEW BY NMPA CHINA

Further company coverage: 2410.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2601801750?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601801750","market":"us","top_or_hot":-1,"title":"BRIEF-TYK Medicines' Asandeutertinib (TY-9591) To Be Included In List Of Products For Priority Review","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-TYK Medicines' Asandeutertinib (TY-9591) To Be Included In List Of Products For Priority Review</title></head><body><p><span>Jan 7 (Reuters)</span><span> - </span>TYK Medicines Inc <span>2410.HK</span>:</p><ul><li><p>ASANDEUTERTINIB (TY-9591) TO BE INCLUDED IN LIST OF PRODUCTS FOR PRIORITY REVIEW BY NMPA CHINA</p></li></ul><p>Further company coverage: <span>2410.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-TYK Medicines' Asandeutertinib (TY-9591) To Be Included In List Of Products For Priority Review</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-TYK Medicines' Asandeutertinib (TY-9591) To Be Included In List Of Products For Priority Review\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-07 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-TYK Medicines' Asandeutertinib (TY-9591) To Be Included In List Of Products For Priority Review</title></head><body><p><span>Jan 7 (Reuters)</span><span> - </span>TYK Medicines Inc <span>2410.HK</span>:</p><ul><li><p>ASANDEUTERTINIB (TY-9591) TO BE INCLUDED IN LIST OF PRODUCTS FOR PRIORITY REVIEW BY NMPA CHINA</p></li></ul><p>Further company coverage: <span>2410.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02410","symbol_name":"同源康医药-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260107:nFWN3Y802O:1","article_id":"2601801750","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601801750","pubTimestamp":1767797112,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-TYK Medicines' Asandeutertinib (TY-9591) To Be Included In List Of Products For Priority ReviewJan 7 (Reuters) - TYK Medicines Inc 2410.HK:ASANDEUTERTINIB (TY-9591) TO BE INCLUDED IN LIST OF PRO","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02410":"同源康医药-B","BK1161":"生物科技"},"translate_title":"简介-TYK Medicines的Asandeutertinib（TY-9591）将被纳入优先审评产品名单","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02410":0.9},"content_text":"BRIEF-TYK Medicines' Asandeutertinib (TY-9591) To Be Included In List Of Products For Priority ReviewJan 7 (Reuters) - TYK Medicines Inc 2410.HK:ASANDEUTERTINIB (TY-9591) TO BE INCLUDED IN LIST OF PRODUCTS FOR PRIORITY REVIEW BY NMPA CHINAFurther company coverage: 2410.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}